Evaluation of Selected Fetal Ultrasound Abnormalities BETA
This revision integrates prior cfDNA/serum screening, diagnostic testing, gestational age, isolation status, quantitative measurements, and severity features into each pathway.
Key principle: negative cfDNA can substantially change management of an isolated soft marker, but it does not replace diagnostic testing when a structural abnormality, multiple abnormalities, fetal effusion, or hydrops phenotype is present.
-
For educational use by medical professionals.
This tool is intended to support, not replace, clinical judgment.
Recommendations are based on published guidance and selected medical
literature and may not apply to every patient. Clinical decisions should
be individualized and based on the complete clinical situation, current
guidelines, and consultation with appropriate specialists when needed.
Clinical context used across findings
Enter this once. Relevant pathways use it automatically.
1. Select a fetal ultrasound finding
The library now includes soft markers, structural anomalies, and high-risk physiologic findings.
2. Enter focused details
Questions and quantitative fields change with the selected finding.
Select a finding to begin.
3. Dynamic clinical output
Select a finding and enter the available details.
Reference framework
Publication version should retain source links/PMIDs and undergo local clinical review before deployment.
Master reference library
- SMFM Consult Series #75 (2026). Evaluation and management of non-immune hydrops fetalis.
- SMFM Consult Series #74 (2025). Cell-free DNA screening for aneuploidies: updated guidance.
- SMFM Consult Series #57 (2021; reaffirmed 2025). Isolated soft ultrasound markers for aneuploidy.
- SMFM Consult Series #52 (2020; reaffirmed 2024). Diagnosis and management of fetal growth restriction.
- SMFM Consult Series #46 (2018; reaffirmed 2024). Polyhydramnios.
- SMFM Consult Series #45 (2018; reaffirmed 2024). Mild fetal ventriculomegaly.
- SMFM Consult Series #42 (2017; reaffirmed 2024). Role of ultrasound after cfDNA screening.
- AAP Clinical Report (2025). Perinatal urinary tract dilation: pre/postnatal imaging and follow-up.
- Nguyen HT, et al. (2014). Multidisciplinary UTD classification system.
- Jani J, et al. Observed/expected lung-to-head ratio in congenital diaphragmatic hernia.
- CPAM/CVR literature. CVR is useful for serial risk assessment, but a single 1.6 threshold should not be treated as a validated probability cutoff.